受累游离轻链与单克隆峰在MGUS进展为多发性骨髓瘤中的比较评估
这项区域范围研究纳入4756人,识别987例MGUS患者,评估基线因素及随访中受累游离轻链(iFLC)和M峰演变对进展为多发性骨髓瘤(MM)的预测价值。中位随访5年每季度监测,发现基线iFLC>100 mg/L、M峰>1.5 g/dL和年龄>65岁均独立增加进展风险;具备任意两项或三项风险因素者5年累积进展概率为31%,无风险因素者为2%。随访中iFLC>100 mg/L持续与进展风险增加相关,建议将iFLC纳入所有MGUS患者的监测工具。
要点
- 基线iFLC>100 mg/L、M峰>1.5 g/dL和年龄>65岁均独立增加MGUS进展风险。
- 具备任意两项或三项风险因素者5年累积进展概率为31%,无风险因素者为2%。
- 随访中iFLC>100 mg/L持续与进展风险增加相关,建议所有MGUS患者监测iFLC。
核心结论
- 基线iFLC>100 mg/L、M峰>1.5 g/dL和年龄>65岁均独立与MGUS进展为MM风险增加相关。
- 具备任意两项或三项风险因素者5年累积进展概率为31%,无风险因素者为2%。
- 随访中iFLC>100 mg/L持续与进展风险增加相关,建议将iFLC作为所有MGUS患者的监测工具。
研究设计与样本
- 区域范围研究,纳入4756人,识别987例MGUS患者。
- 评估基线因素及随访中受累游离轻链(iFLC)演变对进展为MM的风险。
- 每季度监测iFLC和M峰,中位随访5年。
主要发现
- 基线时进展者iFLC显著高于未进展者。
- M峰>1.5 g/dL、年龄>65岁和iFLC>100 mg/L均独立与MGUS进展为MM风险增加相关。
- 具备任意两项或三项风险因素者5年累积进展概率为31%,无风险因素者为2%。
- 随访中iFLC>100 mg/L持续与进展风险增加相关。
关键数值与推荐
- 风险因素:M峰>1.5 g/dL、年龄>65岁、iFLC>100 mg/L。
- 具备任意两项或三项风险因素者5年累积进展概率为31%,无风险因素者为2%。
- 随访中iFLC>100 mg/L持续与进展风险增加相关。
临床怎么用
- 建议将iFLC纳入所有MGUS患者的监测工具。
- 建议对所有高风险患者每季度监测。
- 建议基线时根据年龄、M峰和iFLC对MGUS进展风险进行分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal plasma cell disorder, with a 1% yearly risk of progression to multiple myeloma (MM). Evolution of M-spike and serum free light chain (sFLC) during follow-up could identify patients at high risk of progression. In this region-wide study, including 4756 individuals, 987 patients with MGUS were identified, and baseline factors as well as evolving involved FLC (iFLC) were evaluated as potential markers for risk of progression from MGUS to MM. Furthermore, evolving iFLC and M-spike were assessed quarterly for a median of 5 years. At baseline, patients that progressed had significantly higher iFLC compared to non-progressors. The risk factors of M-spike >1.5 g/dL, age >65 years and iFLC >100 mg/L were all independently associated with increased risk of MGUS to MM progression. For patients that had any two or three risk factors, the 5-year cumulative probability of progression was significantly higher (31%) compared to no risk factors (2%). Evolving iFLC >100 mg/L during follow-up was consistently associated with increased risk of progression. Based on our observations, we propose to include iFLC as a monitoring tool for all MGUS patients. Furthermore, we recommend a quarterly monitoring in all high-risk patients. Finally, we suggest that the risk of MGUS progression should be stratified with age, M-spike, and iFLC at baseline.
引用
- Gran C, Liwing J, Wagner AK, et al. Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. Am J Hematol. 2020. PMID: 32936979. doi:10.1002/ajh.25999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。